Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in people with ...

PLAINSBORO, N.J., Aug. 15, 2025 /PRNewswire/ -- Novo Nordisk (NVO) today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 ...

The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.

At Wegovy.com, patients can check to see if their commercial insurance provider covers Wegovy®, which could lead to paying as little as $0/month. Full terms and conditions for all offers are available ...

PLAINSBORO, N.J., June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy ® (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers, a global ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled WEgovy Real ...

COPENHAGEN (KVOA) - Novo Nordisk said Wednesday that late-stage trial results for its once-daily obesity pill showed “significant” weight reduction and tolerability in line with its blockbuster Wegovy ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...

Weight loss drugs like Wegovy and Ozempic have helped millions in their weight loss (and diabetes) journeys. Now, Novo Nordisk—the creator of Wegovy—has published results of a once-daily oral ...